Morningstar - PENSKE AUTOMOTIVE GROUP INC (PAG) Expansion Into Used Vehicles and Trucking Should Continue for Penske

Report

Morningstar

David Whiston

EUR 100.00 For Business Accounts Only

Expansion Into Used Vehicles and Trucking Should Continue for Penske

Penske Automotive Group's fourth-quarter results gave us no reason to change our fair value estimate. Adjusted diluted EPS of $1.11 missed consensus of $1.15 but was still a fourth-quarter record and grew 9.9% year over year. Revenue grew 0.8% and slightly missed consensus, while same-store retail automotive revenue fell 0.9%. Weakness came from new-vehicle sales, which suffered from inventory shortages of German automakers' vehicles due to earlier noncompliance with WLTP emission rules in Europ...

19/03/2019 12 EN

Underlying

PENSKE AUTOMOTIVE GROUP INC

Penske Automotive Group is a transportation services company that operates automotive and commercial truck dealerships and distributes commercial vehicles, diesel engines, gas engines, power systems and related parts and services. The company has four segments: Retail Automotive, consisting of its retail automotive dealership operations; Retail Commercial Truck, consisting of its retail commercial truck dealership operations in the United States and Canada; Other, consisting of its commercial vehicle and power systems distribution operations and other non-automotive consolidated operations; and Non-Automotive Investments, consisting of its equity method investments in non-automotive operations.

See profile

US70959W1036 New York Stock Exchange United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

David Whiston

Other Reports on these Companies

SmartInsider

Penske Automotive Group Inc: 1 director

A director at Penske Automotive Group Inc sold 3,158 shares at 167.101USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The n...

Free Trial

June 11, 2025 June 11, 2025 1 EN

Moody's Investors Service

Moody's Ratings announces completion of a periodic review of ratings of Penske Automotive Group, Inc.

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Penske Automotive Group, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 10 March 2025 in which we reassessed the appropriateness of the ratings in th...

March 17, 2025 March 17, 2025 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Breaking Out We are seeing signs that this 2+ month consolidation in the S&P 500 and Nasdaq 100 (QQQ) is ready to break out to the upside. Part of that is the obvious; both the SPX and QQQ are breaking out to marginal new highs. The other part that has kept us bullish this whole time is that market dynamics have remained risk-on, which we have discussed on a weekly basis. Bottom line: our outlook remains bullish as long as the S&P 500 remains above 5770-5850. Our recommendations to "buy the pullbacks" since the day before the election, and also throughout the second hal...

EUR 42.54

February 19, 2025 February 19, 2025 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Expansion Into Used Vehicles and Trucking Should Continue for Penske

Penske Automotive Group Inc: 1 director

Moody's Ratings announces completion of a periodic review of ratings of Penske Automotive Group, Inc.

Vermilion Compass: Weekly Equity Strategy

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe